secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0002019410-26-000019
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone
--------------------------------------------------------------------------------

- Borrowed $400M initial term loan to repay existing credit agreement from January 2023.
- Additional $300M delayed draw facility for acquisitions available through August 2027.
- Uncommitted incremental capacity up to $500M; loans priced at SOFR + 5.00%.
- Credit agreement matures April 2031; secured by substantially all assets.
- Must maintain minimum $50M qualified cash tested quarterly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm
  HTML page:      https://secwatch.observer/filing/0002019410-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer